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Strengths and limitations of this study
 ► We analysed a large administrative dataset with 
detailed patient- level information to provide recent 
evidence on benzodiazepine prescription in older 
adults in Switzerland.
 ► The Swiss context with its decentralised system but 
homogeneous benefit package offers an opportuni-
ty to study regional variation that can shed light on 
cultural differences in healthcare use.
 ► We restricted our analysis to the cantons in which 
direct dispensing by physicians is not allowed; 
our sample is therefore not representative of all 
Switzerland.
 ► By relying on claims data, we have only limited di-
agnostic information at the individual level and we 
were therefore unable to identify the reason for ben-
zodiazepine prescriptions.
 ► We only investigate association between prescrip-
tion, hospitalisations and costs, and are not able to 
make any causal claim.
AbStrACt
Objective This study aimed to examine the prevalence 
and determinants of benzodiazepine prescription among 
older adults in Switzerland, and analyse association with 
hospitalisation and costs.
Design Retrospective analysis of claims data.
Setting The study was conducted in nine cantons in 
Switzerland.
Participants Older adults aged 65 years and older 
enrolled with a large Swiss health insurance company 
participated in the study.
Primary and secondary outcome measures The 
primary outcome was prevalence of benzodiazepine 
prescription. The secondary outcomes were (1) 
determinants of any benzodiazepine prescription; 
(2) the association between any prescription and the 
probability of hospitalisation for trauma and (3) the 
association between any prescription and total healthcare 
expenditures.
results Overall, 69 005 individuals were included in the 
study. Approximately 20% of participants had at least 
one benzodiazepine prescription in 2017. Prescription 
prevalence increased with age (65–69: 15.9%; 70–74: 
18.4%; 75–80: 22.5%; >80: 25.8%) and was higher in 
women (25.1%) compared with men (14.6%). Enrollees 
with the highest deductible of Swiss Francs (CHF) 2500 
were 70% less likely to receive a prescription than 
enrollees with the lowest deductible of CHF 300 (adjusted 
OR=0.29, 95% CI 0.24 to 0.35).
Individuals with at least one prescription had a higher 
probability of hospitalisation for trauma (OR=1.31, 95% CI 
1. 20 to 1.1.44), and 70% higher health care expenditures 
(β=0.72, 95% CI 0. 67 to 0.77). Enrollees in canton Valais 
were three times more likely to receive a prescription 
compared to enrollees from canton Aargau (OR=2.84, 95% 
2.51 to 3.21).
Conclusions The proportion of older adults with at least 
one benzodiazepine prescription is high, as found in the 
data of one large Swiss health insurance company. These 
enrollees are more likely to be hospitalised for trauma and 
have higher healthcare expenditures. Important differences 
in prescription prevalence across cantons were observed, 
suggesting potential overuse. Further research is needed 
to understand the drivers of variation, prescription patterns 
across providers, and trends over time.
IntrODuCtIOn
Benzodiazepines are among the most 
prescribed psychotropic drugs in high- income 
countries, widely used for treating anxiety and 
sleep disorders. Estimates of adult benzodiaz-
epine consumption (≥18 years) range from 
5% in the USA to over 16% in some European 
countries.1 2 There are growing concerns 
about the potentially inappropriate use of 
benzodiazepines, particularly when used for a 
long period of time.3 4 Studies have found an 
increase in benzodiazepine prescription with 
age in both men and women and a positive 
association with health- related factors such as 
depression and chronic disease.1 5 6 Benzodi-
azepines have been ranked among the most 
misused drugs, particularly for dependence.7 
Moreover, guidelines discourage prolonged 
use of benzodiazepines especially among 
older people due to severity of adverse effects, 
particularly those associated with the central 
nervous system.8 9 Indeed, when used for long 
 o
n
 January 9, 2020 at Basel University. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-031156 on 6 January 2020. Downloaded from 
2 Luta X, et al. BMJ Open 2020;10:e031156. doi:10.1136/bmjopen-2019-031156
Open access 
periods, benzodiazepines may lead to dependency, trau-
matic falls and fracture,10 11 hospitalisation and death,12–14 
leading to increased healthcare costs.8 15 16
In 2019, the American Geriatrics Society9 published 
an update of the Beers Criteria to guide prescription in 
the elderly population.17 It recommends avoiding the use 
of benzodiazepines in elderly patients due to increased 
sensitivity to these drugs and decreased metabolic rate 
of long- acting agents. Moreover, use for longer than 4 
weeks may be potentially problematic.18Despite the lack 
of evidence supporting their use beyond short periods, 
benzodiazepines are often prescribed for longer periods 
than recommended, particularly among those aged ≥65.19
In Switzerland, the Choosing Wisely Switzerland 
(‘smarter medicine’) top-5 list of low- value interven-
tions for geriatrics includes benzodiazepines (https://
www. smartermedicine. ch) and makes the following 
recommendation: “Don’t use benzodiazepines or other 
sedative- hypnotics in older adults as first choice for 
insomnia, agitation or delirium and avoid prescription at 
discharge”.20 Use of benzodiazepines is, however, recom-
mended for alcohol withdrawal symptoms /delirium 
tremens or severe generalised anxiety disorder unre-
sponsive to other therapies. Although concern exists 
regarding potential overuse, limited information is avail-
able regarding patterns of use and its impact in older 
adults. For instance, a study conducted in 2007 including 
520 000 participants from the general adult population 
found that 9.1% received at least one benzodiazepine 
prescription within a period of 6 months.21
In this study, we use routine health insurance claims 
data to measure the prevalence of benzodiazepine 
prescription among individuals aged ≥65 in Switzerland. 
We further assess patterns of benzodiazepine prescription 
(eg, number of prescriptions, defined daily dose (DDD)), 
determinants of prescription, association with hospital-
isation and healthcare costs. In addition, we study differ-
ences in the prevalence of prescription across cantons 
to assess potential unwarranted variation and identify 
regions in need of concerted deprescribing efforts.
MethODS
Setting
Switzerland is a confederation of 26 cantons (states) with 
a total population of 8.4 million inhabitants. There are 
four official languages: German (63%), French (22.7%), 
Italian (8.1%) and Romansch (0.5%). While the Swiss 
healthcare system performs well in international compar-
isons,22 23 it is also one of the most expensive in the world. 
The regulation and organisation of healthcare takes 
place at the three main political levels, that is, central 
government, cantons and municipalities, with cantons 
playing a central role in delivery and financing of health-
care services.24 This gives rise to disparate cantonal health 
systems under the umbrella of a common central regula-
tion. Health insurance is mandatory and covers illness, 
maternity and accidents for all insured individuals who 
are free to choose among registered health insurance 
companies that offer the same benefit package. The stan-
dard plan offers freedom of provider choice and direct 
access to secondary care. Enrollees can choose their 
deductible level (options range from CHF 300 to 2500) 
and, in return for a lower premium, they can choose 
alternative healthcare plans (HCPs), with either a general 
practitioner (GP) or a medical call centre as the first point 
of contact.25 Gatekeeping plans require enrollees to see 
a GP for referral to specialists, and managed care plans 
typically restrict access to a list of providers. Premiums 
are not risk- rated but can vary significantly across regions. 
Participation of households to healthcare expenditures 
is important and includes deductibles, co- payments and 
out- of- pocket expenses, giving rise to a particularly regres-
sive financing system.26
Study design and participants
We conducted a cross- sectional analysis of claims data 
to study benzodiazepine prescriptions in enrollees aged 
≥65 in 2017. We restricted our analysis to the nine Swiss 
cantons (ie, Aargau, Basel, Freiburg, Geneva, Jura, 
Neuchatel, Ticino, Vaud and Valais) in which direct medi-
cation dispensing by physicians is not allowed, as such 
prescriptions may not be captured with enough accuracy 
in the data.
Data sources
We obtained data from Groupe Mutuel, which is one of 
the largest health insurance companies in Switzerland, 
covering some 981 160 individuals with mandatory health 
insurance in 2019. The database provides information 
on demographic characteristics of enrollees including 
age, sex and canton of residence, as well as information 
on insurance plan (deductible level and type of contract 
(types of contract include basic option, gatekeeping, 
telephone- based gatekeeping, as well as managed care 
(HMO))). In addition, the data include information 
on hospitalisations with the associated diagnosis- related 
group (DRG), total costs covered by mandatory health 
insurance, comorbiditiesi derived from medication use,27 
drug prescription information including anonymous 
prescriber identifier, Anatomical Therapeutic Chemical 
(ATC) classification system codes and a more detailed 
Swiss classification code (ie, Pharmacode), number of 
packs and prescription date. The following ATC codes 
were used to identify benzodiazepine prescriptions : 
N05BA and N05CD. We identified two types of hospitalisa-
tions using Swiss DRG codes: (1) those potentially related 
i Attention deficit hyperactivity disorder (ADHD), asthma, 
autoimmune diseases, cystic fibrosis/pancreatic enzyme, high 
cholesterol, chronic obstructive pulmonary disease (COPD)/
severe asthma, Crohn’s disease/ulcerative colitis, depression, 
diabetes, type 2 diabetes, epilepsy, glaucoma, heart disease, 
HIV/AIDS, hormone- sensitive cancer, hypertension, cancer, 
kidney disease, brain or spinal cord diseases, neuropathic pain, 
Parkinson’s disease, psychosis, Alzheimer, and addiction, rheu-
matism, thyroid disease, transplantation
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to benzodiazepine use, that is, trauma- related (online 
supplementary file 1), and (2) all other hospitalisations.
Statistical analysis
We first described participants’ characteristics including 
demographics (ie, age categorised into four main groups: 
65–69, 70–74, 75–80 and >80 years, sex, canton of resi-
dence) and insurance details (deductible and plan type), 
and analysed differences in characteristics between those 
with and without any benzodiazepine prescription. We 
also analysed how the prevalence of prescription vary by 
age and canton. Intensity of potential benzodiazepine 
use among individuals with at least one prescription was 
captured using number of benzodiazepine prescriptions 
and total number of DDD. We also produced an estimate 
of the treatment duration, and computed mean daily 
dose by combining information on prescription dates 
and DDDs.28 Finally, we analysed (1) the determinants 
of any benzodiazepine prescription and (2) the associ-
ation between any prescription and the probability of 
trauma- related hospitalisations using logistic regression, 
as well as (3) the association between any prescription 
and total healthcare expenditures using a linear regres-
sion with log- transformed costs.29 This specification was 
preferred to two- part or zero- inflated models as we have 
a highly skewed distribution of costs, but only a small 
proportion of enrollees with zero cost. Control variables 
included age, canton of residence, deductible level, type 
of contract, total number of non- trauma hospitalisations 
as a proxy for health status and comorbidities. In addition 
to ORs and regression coefficients, we report predicted 
outcomes (ie, hospitalisation rate and healthcare expen-
ditures) to reflect the contribution of each value of each 
covariate to the outcomes of interest, all else being equal.
Data management and analysis were conducted using 
Stata V.15.1 (StataCorp LP, College Station, Texas, USA).
Patient and public involvement
Patients and the public were not involved in the design or 
planning of the study.
30
reSultS
Descriptive statistics
Our study population consisted of 69 005 individuals aged 
65 and older (table 1). The mean age for all enrollees was 
75.1 years and over half were women (55%). The majority 
of participants (57%) had a basic health insurance plan 
without a specific model and chose the lowest deductible 
level of CHF 300 (55%). Among all included individ-
uals, 20.4% had at least one benzodiazepine prescription 
during the study period.
The prevalence of any benzodiazepine prescription 
increased with age and was highest (25.8%) among age 
group 80 and older. Women had higher (25.1%) prev-
alence compared with men (14.6%). Study participants 
with a basic health insurance (22.1%) and those with the 
lowest deductible level (23.6%) had higher prevalence 
of benzodiazepine prescription. Overall, over half of 
the study participants (55.7%) had no comorbidity and 
about a third had one comorbidity (32%). The highest 
prevalence of benzodiazepine prescription was observed 
among those with five or more comorbidities (44%).
Figure 1 shows variation of prescription prevalence by 
age and canton of residence. In all cantons, except in 
canton of Fribourg where prevalence dropped among 
older enrollees, prevalence increased steadily with age 
to reach about 30% for the oldest age group in some 
cantons. We also observe important variation between 
cantons, with prevalence varying by a factor of 2 between 
the highest and the lowest prescribing cantons. Of note, 
the two lowest prescribing cantons are in the German- 
speaking part of the country, whereas the other cantons 
are in the French- speaking or Italian- speaking regions.
A total of 75 130 benzodiazepine prescriptions were 
filled in 2017. The most commonly prescribed products 
were lorazepam (39.9%), oxazepam (16.4%) and broma-
zepam (13.1%) (table 2). The majority of individuals with 
at least one prescription received intermediate- acting 
benzodiazepine agents (67.7%), followed by long- acting 
benzodiazepines (25%) and only a small proportion 
(7.4%) received short- acting benzodiazepines.
The mean number of prescriptions among those with at 
least one prescription was 4.9 (SD 5.4, median 4), and the 
mean DDD was 111.23 (SD 145.4, median 60). About one- 
third of users received at least five prescriptions during 
the year and 40% were prescribed the equivalent of 90 
DDD or more. More importantly, the estimated treatment 
duration is above 15 days for 80% of users, suggesting 
high prevalence of long- term use. By combining infor-
mation on prescription dates and DDD, we calculated a 
mean daily dose of 0.85 (SD 1.65, median 0.70).
Determinants of benzodiazepine prescription
Logistic regression results are presented in table 1. The 
probability of any benzodiazepine prescription increased 
with age. For example, the adjusted OR was 1.29 (95% CI 
1.22 to 1.36) for enrollees aged 75–80 and 1.41 (95% CI 
1.34 to 1.49) for those aged 80 and older (ref: 65–69). Men 
were 50% less likely to be prescribed benzodiazepines as 
women (adjusted OR=0.53, 95% Cl 0.51 to 0.55). The 
model also revealed significant differences in prescribing 
patterns between cantons, with for instance prevalence of 
prescription being nearly three times higher in canton 
Valais than in the reference canton of Aargau (OR=2.84, 
95% CI 2.51 to 3.21).
We observed an association between deductible level 
and benzodiazepine prescription. Enrollees with higher 
deductibles were less likely to receive a prescription. For 
instance, enrollees with the highest deductible level of 
CHF 2500 were 70% less likely to receive a prescription 
than enrollees with a deductible of CHF 300 (OR=0.29, 
95% CI 0.24 to 0.35). Having chronic conditions was asso-
ciated with benzodiazepine prescription. For example, 
among individuals with one chronic condition, the OR 
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Table 1 Sample characteristics, 2017 (n=69 005)
N (%)
% with any 
benzodiazepine 
prescription
Adjusted % with 
any benzodiazepine 
prescription*
Unadjusted OR 
(95% CI)
Adjusted OR 
(95% CI)
Age groups
  65–69 19 553 (28.3) 15.9 20.4 – –
  70–74 17 773 (25.8) 18.4 21.4 1.18 (1.12 to 1.25) 1.08 (1.02 to 1.15)
  75–80 14 820 (21.5) 22.5 23.6 1.53 (1.45 to 1.62) 1.29 (1.22 to 1.36)
  80+ 16 859 (24.4) 25.8 24.5 1.83 (1.74 to 1.93) 1.41 (1.34 to 1.49)
Sex
  Female 38 259 (55.4) 25.1 24.5 – –
  Male 30 746 (44.6) 14.6 15.1 0.51 (0.49 to 0.53) 0.53 (0.51 to 0.55)
Canton
  NE 3594 (5.2) 24.9 23.2 3.53 (3.09 to 4.05) 2.72 (2.37 to 3.12)
  VS 12 159 (17.6) 24 23.9 3.37 (2.99 to 3.79) 2.84 (2.51 to 3.21)
  GE 12 753 (18.5) 23.1 21.8 3.21 (2.85 to 3.61) 2.50 (2.21 to 2.83)
  JU 1672 (2.4) 22 21.7 3.00 (2.56 to 3.53) 2.49 (2.11 to 2.93)
  TI 3591 (5.2) 21.6 22.8 2.94 (2.56 to 3.37) 2.65 (2.31 to 3.05)
  VD 23 363 (33.9) 19.4 19.2 2.57 (2.29 to 2.88) 2.11 (1.88 to 2.39)
  FR 5742 (8.3) 18.2 19.4 2.38 (2.09 to 2.70) 2.15 (1.88 to 2.46)
  BS 2145 (3.1) 12.5 12.9 1.52 (1.28 to 1.80) 1.29 (1.09 to 1.54)
  AG 3986 (5.8) 8.6 10.4 – –
Insurance plan
  Basic plan 39 310 (57.0) 22.1 21.1 – –
  Gatekeeping 14 706 (21.3) 19.6 20.4 0.86 (0.82 to 0.90) 0.96 (0.91 to 1.01)
  Phone- based gatekeeping 8776 (12.7) 14.9 17.6 0.61 (0.58 to 0.65) 0.79 (0.74 to 0.85)
Managed care (HMO) 6213 (9.0) 19.3 19.4 0.84 (0.79 to 0.90) 0.89 (0.83 to 0.96)
Deductible (CHF)
  300 38 037 (55.1) 23.6 22.3 – –
  500 22 415 (32.5) 19.7 19.5 0.79 (0.76 to 0.83) 0.83 (0.80 to 0.87)
  1000 2004 (2.9) 11.9 15 0.44 (0.38 to 0.50) 0.60 (0.52 to 0.69)
  1500 3667 (5.3) 8.6 12.4 0.31 (0.27 to 0.34) 0.47 (0.42 to 0.54)
  2000 395 (0.6) 6.6 10 0.23 (0.15 to 0.34) 0.37 (0.25 to 0.56)
  2500 2487 (3.6) 5.1 8 0.17 (0.15 to 0.21) 0.29 (0.24 to 0.35)
Comorbidities (PCG)
  0 38 430 (55.7) 15.1 15.7 – –
  1 22 231 (32.2) 24.6 24 1.83 (1.76 to 1.91) 1.73 (1.66 to 1.80)
  2 6813 (9.9) 32.2 29.8 2.67 (2.52 to 2.83) 2.36 (2.22 to 2.50)
  3 1317 (1.9) 38.2 34.3 3.47 (3.09 to 3.89) 2.94 (2.61 to 3.30)
  4 189 (0.3) 41.8 37.1 4.03 (3.02 to 5.39) 3.35 (2.49 to 4.51)
  5+ 25 (0.0) 44 36.6 4.41 (2.00 to 9.72) 3.27 (1.46 to 7.32)
Overall 20.4
 Outcomes Benzodiazepine users (n=14 072) Non- users (n=54 925)
Healthcare expenditures, mean (SD) 15 573 (19 040) 9111 (14 848)
Hospitalisation (any), N (%) 3841 (27.3) 9298 (16.9)
Hospitalisation (trauma), N (%) 760 (5.4) 1925 (3.5)
*Adjusted for age, sex, canton, insurance plan, deductible (CHF) and comorbidities.
PCG, pharmaceutical cost group.
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Figure 1 Prescription prevalence by age groups and canton, 2017.
was 1.73 (95% CI 1.66 to 1.80) and increased to 3.27 
among those with five or more comorbidities (95% CI 
1.46 to 7.32).
Association with hospitalisations and healthcare expenditures
Overall, 19% of individuals had at least one hospital admis-
sion during the study period. Individuals with a benzodi-
azepine prescription were more likely to be hospitalised 
for any cause (27.3% vs 16.9%) and for trauma (5.4% vs 
3.5%) compared to non- users. Total healthcare expendi-
tures were higher for those with a prescription than for 
non- users (CHF 15 573 vs 9111). Table 3 shows the asso-
ciation between benzodiazepine prescription, hospitalisa-
tions and healthcare expenditures. Individuals with any 
benzodiazepine prescription had higher probability of 
being hospitalised for trauma (OR=1.31, 95% CI 1.20 to 
1.44) table 3. As expected, hospitalisation rate increased 
with age and comorbidities. Our models of total health-
care expenditures showed that those with at least one 
prescription had 70% higher expenditures compared to 
non- users (β=0.72, 95% CI 0. 67 to 0.77).
DISCuSSIOn
In this retrospective analysis of insurance claims data, the 
proportion of individuals aged 65 years and older with 
at least one prescription of benzodiazepines in 2017 was 
about 20%. The prevalence of prescription increased 
with age and was higher among women. We also found 
important variation in prescription prevalence across 
cantons, with prevalence ranging from 16% to 31%. 
Having more than one comorbidity and having a lower 
deductible was associated with a higher probability 
of benzodiazepine prescription. Finally, we found an 
association between benzodiazepine prescription, hospi-
talisation for trauma and healthcare expenditures.
This is one of the first studies investigating benzodiaz-
epine prescription in older adults in Switzerland. A study 
conducted in the general population21 showed a preva-
lence of benzodiazepine dependence of 16%–20% with 
many patients (49.3%) receiving benzodiazepines on a 
long- term basis and 8.3% receiving benzodiazepines in 
high doses. A recently published Swiss study using claims 
data found no association between use and the risk of 
Alzheimer’s disease,31 contrary to previous evidence.32 In 
other countries the prevalence of benzodiazepine use in 
the elderly population ranged from 15% to 31%.1 6 33–35 
In our study, about 20% of enrollees received at least one 
benzodiazepine prescription in 2017, with two- thirds of 
them receiving the equivalent of 30 DDD or more, and 
80% with estimated treatment durations longer than 2 
weeks. Thus, considering that use is typically not recom-
mended beyond 2–4 weeks of treatment,17 36 the preva-
lence of benzodiazepine overuse among older people in 
Switzerland is likely to be as high as 16%. This proportion 
might be twice higher in non- German- speaking cantons, 
among women over 80 years old and in multimorbid 
people.
High prevalence of benzodiazepine prescription 
among older adults appears to be common in many parts 
of the world. For example, a study in the USA found 
that 5.2% of the adult population were benzodiazepine 
users.1 People receiving prescription from a psychiatrist 
were more likely to be long- term users and this tendency 
increased with age (33% in younger adults and 53.5% in 
older adults). In Australia, 16% of the adults aged 65 years 
and older had at least one benzodiazepine prescription 
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Table 2 Details on benzodiazepine prescriptions, 2017
N
% of all 
benzodiazepine 
prescriptions
Panel A: prescribed 
benzodiazepines (n=75 130)
Anxiolitics (N05BA)
  Intermediate acting
   Lorazepam 29 945 39.9
   Oxazepam 12 298 16.4
   Alprazolam 5843 7.8
   Lorazepam+Diphenhydramine 1557 2.1
  Long acting
   Bromazepam 9840 13.1
   Clorazepate 3782 5.0
   Prazepam 1122 1.5
   Others (ie, diazepam, clobazam, 
kétazolam)
456 0.6
   Hypnotics and sedatives (N05CD)
  Short acting
   Midazolam 3524 4.7
   Triazolam 2039 2.7
  Intermediate acting
   Lormatezepam 755 1.0
   Temazepam 366 0.5
  Long acting
   Flurazepam 2461 3.3
   Flunitrazepam 838 1.1
   Nitrazepam 284 0.4
Mean SD Median IQR
Panel B: prescriptions 
among users (n=14 072)
No. of benzodiazepine 
prescriptions
4.94 5.43 4 6
DDD 111.23 145.40 60 128
Mean daily dose 0.85 1.65 0.70 0.62
No. of different prescribers 1.25 0.57 1 0
No. of different drugs 
prescribed (any type)*
10.2 7.2 9 9
N %
No. of benzodiazepine prescriptions
  1 3839 27.3
  2–5 5278 37.5
  5–10 3427 24.4
  10+ 1528 10.9
DDD
  0–30 5046 35.9
  30–90 3371 24.0
  90–180 3142 22.3
  180–360 1713 12.2
  360+ 800 5.7
Estimated treatment duration (days)
Continued
N %
  0–15 2936 20.1
  15–90 2095 14.9
  90–180 2182 15.5
  180–270 2440 17.3
  270+ 4419 31.4
Mean daily dose
  0–0.5 5317 37.8
  0.5–1 6893 50.0
  1–2 1429 10.2
  2+ 433 3.1
*Total number of prescriptions of different therapeutic/pharmacological 
subgroups (ATC 4- digit).
DDD, defined daily dose.
Table 2 Continued
with higher prevalence in women and those aged 65 and 
older.34 A recent German retrospective study including 
over 32 000 older people showed that the proportion 
of patients receiving benzodiazepine therapy for over 6 
months was approximately 15%–20%. Similar to our find-
ings, use of benzodiazepines was more frequent in older 
people, patients treated in neuropsychiatric practices, 
and people diagnosed with dementia, sleep disorders or 
depression.6
The fact that over three quarters of individuals with at 
least one benzodiazepine prescription are long- term users 
reflects the challenge of discontinuing such treatment. 
Research suggests that the main barriers to reducing or 
stopping prescription of psychotropic drugs in clinical 
practices are patient perceived difficulty to stop the medi-
cation and lack of alternative therapies such as cognitive 
behavioural therapy.37 Moreover, healthcare providers 
may not recommend discontinuing benzodiazepines due 
to concerns related with withdrawal symptoms, which may 
occur in up to 50% of patients.38 Our findings are consis-
tent with previous research33 39 40 showing higher prev-
alence of prescription among women. The increase of 
benzodiazepine prescription with the number of chronic 
conditions can be partly explained by poorer quality of 
sleep and more prevalent anxiety in this group. It is also 
possible that more frequent physician visits increase the 
risk of initiating hypnotic treatment.
We found higher rates of trauma- related hospital admis-
sions and higher healthcare expenditures in individuals 
with at least one benzodiazepine prescription than in 
non- users. Previous research has consistently reported 
that benzodiazepine use is associated with significant 
increase in risk of falls.41–43 A meta- analysis reported up 
to 50% increase in risk of falls among benzodiazepine 
users.44 Fall- related injuries are one of the most expensive 
medical conditions and may have major economic conse-
quences on healthcare systems.45 Research from the USA 
suggests that the average cost for fall injury is over $30 000 
and increases with age.46
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Table 3 Association with hospitalisation and costs
Variables
Outcome: any hospitalisation for trauma
Logistic regression
Outcomes: ln(health expenditure)
OLS (β reported)*
OR 95% CI
Predicted % with 
hospitalisation† β 95% CI
Predicted health 
expenditure (in CHF)†
Any benzodiazepine 
prescription
            
  No – – 3.6 – – 6400
  Yes 1.31 1.20 to 1.44 4.7 0.72 0.67 to 0.77 13 168
Age             
  65–69 – – 3.9 – – 8504
  70–74 1.15 1.03 to 1.29 4.3 0.37 0.31 to 0.42 11 562
  75–80 1.34 1.20 to 1.51 4.8 0.53 0.47 to 0.58 13 013
  80+ 1.28 1.14 to 1.43 4.6 0.83 0.78 to 0.89 14 494
Sex             
  Female – – 4.4 – – 8923
  Male 0.74 0.69 to 0.81 3.3 −0.12 −0.16 to −0.07 7952
Canton             
  AG – – 4.4 – – 5470
  BS 1.06 0.81 to 1.38 4.7 0.46 0.32 to 0.60 8683
  FR 1.00 0.81 to 1.25 4.4 0.57 0.46 to 0.68 9657
  VD 0.88 0.73 to 1.06 3.9 0.58 0.49 to 0.68 9807
  TI 0.69 0.54 to 0.89 3.1 0.21 0.09 to 0.33 6733
  JU 0.95 0.71 to 1.27 4.2 0.24 0.09 to 0.39 6230
  GE 0.85 0.70 to 1.03 3.8 0.50 0.40 to 0.60 8991
  VS 0.80 0.66 to 0.97 3.6 0.17 0.07 to 0.27 6475
  NE 0.97 0.77 to 1.22 4.3 0.40 0.28 to 0.52 8124
Insurance plan             
  Basic plan – – 4.0 – – 8475
  Gatekeeping 0.91 0.82 to 1.00 3.6 0.09 0.03 to 0.14 9245
  Phone- based 
gatekeeping
0.94 0.83 to 1.07 3.8 −0.12 −0.19 to −0.06 7485
  Managed care (HMO) 0.95 0.82 to 1.10 3.8 −0.04 −0.12 to 0.03 8090
Deductible (CHF)             
  300 – – 4.1 – – 9495
  500 0.95 0.88 to 1.04 3.9 −0.22 −0.26 to −0.17 7656
  1000 0.69 0.52 to 0.92 2.8 −1.01 −1.13 to −0.89 3448
  1500 0.85 0.69 to 1.04 3.5 −1.69 −1.78 to −1.60 1748
  2000 0.68 0.35 to 1.32 2.8 −2.45 −2.71 to −2.18 823
  2500 0.55 0.40 to 0.75 2.3 −3.14 −3.25 to −3.03 409
Comorbidities (PCG)             
  0 – – 3.6 – – 2977
  1 1.19 1.09 to 1.30 4.2 1.35 1.30 to 1.39 11 461
  2 1.21 1.07 to 1.37 4.3 1.58 1.51 to 1.65 14 500
  3 1.39 1.10 to 1.76 4.9 1.78 1.64 to 1.93 17 675
  4 0.22 0.05 to 0.89 0.8 1.94 1.56 to 2.32 20 699
  5+ 1.46 0.34 to 6.27 5.1 2.00 0.96 to 3.03 21 908
Continued
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Variables
Outcome: any hospitalisation for trauma
Logistic regression
Outcomes: ln(health expenditure)
OLS (β reported)*
OR 95% CI
Predicted % with 
hospitalisation† β 95% CI
Predicted health 
expenditure (in CHF)†
Total number of hospital 
admissions (non- trauma)
            
  0 – – 3.4 – – 3704
  1 1.69 1.52 to 1.88 5.7 1.69 1.63 to 1.76 20 131
  2+ 2.03 1.76 to 2.33 6.7 2.22 2.13 to 2.31 34 079
  N 69 005           
*Semielasticity.
†Obtained by predicting the outcome for each value of each covariate, all else being equal.
PCG, pharmaceutical cost group.
Table 3 Continued
Finally, we observed a large variation across cantons in 
the prevalence of benzodiazepine prescription. The vari-
ation could be due to several factors including patient 
and provider characteristics, as well as factors related to 
the organisation of healthcare (eg, guidelines, incentives, 
different local practice patterns). Large differences in 
healthcare utilisation across the three language regions 
(French, German and Italian) have been reported in 
several Swiss studies, which might reflect cultural differ-
ences.47–49 In particular, substantial cantonal varia-
tion in prescriptions for other types of drugs has been 
reported in previous Swiss studies, for example, in Wertli 
et al (2017)50 who found pronounced geographical differ-
ences in prescription of pain medications.
Strengths and limitations
This study has several strengths. First, select data from 
individuals were available with detailed patient- level 
information to provide recent evidence on benzodiaze-
pine prescription in older people in Switzerland. Such 
data are not readily available in the country and previous 
studies have often relied on survey data.21 51 52 In addi-
tion, the Swiss context with its decentralised system but 
homogeneous benefit package offers an opportunity to 
study regional variation that can shed light on cultural 
differences in healthcare use.
Our study has also several limitations. First, we restricted 
our analysis to the cantons in which direct dispensing by 
physicians is not allowed; our sample is therefore not 
representative of all Switzerland. In addition, as we are 
relying on claims data, we have only limited diagnostic 
information at the individual level and we were therefore 
unable to identify the reason for prescription, and we are 
only able to analyse prescriptions filled and not actual 
medication use. Also, our study is likely to underestimate 
prescription prevalence as a share of prescriptions is 
likely to be paid out- of- pocket and therefore not recorded 
in claims data; our findings on the negative association 
between deductible level and benzodiazepines prescrip-
tion could partly reflect this. Also, while our data capture 
information on the number of providers, we were not 
able to identify the type of prescribing physician which 
has been previously identified as an important determi-
nant of benzodiazepine prescription.53 Also, as benzo-
diazepine misuse at older ages may reflect misuse and 
consequent habituation at younger ages, focusing on 
the population aged 65 and older is a limitation. Future 
studies should examine patterns and initiation of prob-
lematic use in different age groups, and persistence of 
misuse over time. Finally, we only investigate association 
between prescription, hospitalisation and costs and are 
not able to make any causal claim.
Implications for clinicians and policy makers
Despite these limitations, our study has important impli-
cations for patients, healthcare providers and policy 
makers. Our results indicate that benzodiazepine overuse 
among older adults is likely to be a public health issue 
in Switzerland. It is thus necessary to analyse the causes 
and the consequences of this phenomenon. Is it driven by 
patient demand or by physician supply, with a minority of 
doctors initiating such treatments? Potential explanations 
of excessive prescription by doctors include inaccurate 
appreciation of the risk–benefit trade- off of the medica-
tion, poor knowledge of alternative treatment options 
or consultation time constraints while facing complex 
psychosocial problems.54 55
In this context, the development of clearer prescription 
guidelines, accompanied with improved monitoring of 
use, might help curb prescription rates. As overuse may 
be driven by variation in prescribing practice, future inter-
ventions could target prescribers in cantons with highest 
prescribing rates. Results shown in this study could also be 
used to set a national benchmark. For instance, authori-
ties could aim for a target of use in adults age 65 and 
older, which would be realistic and reflect what is achiev-
able in some cantons (eg, <10% in use). Future research 
should also look into why some cantons are able to 
achieve such low prevalence compared with others. It will 
also be important to better understand why multimorbid 
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patients consume benzodiazepines more frequently and 
whether the observed associations between benzodiaze-
pine prescription, hospitalisation rates and healthcare 
expenditures reflect causality.
Our findings may be generalised to other developed 
countries that face similar challenges in their healthcare 
system (eg, ageing population and increasing healthcare 
costs).
COnCluSIOnS
We found evidence of high prevalence of prescription in 
this population, in particular in non- German- speaking 
cantons, women over 80 years old and in people with 
comorbidities. Future studies could identify patterns of 
prescription across provider type and trends over time. 
The use of benzodiazepines is high and is associated with 
trauma and healthcare expenditures, with variability 
across cantons, suggesting regional/prescriber directed 
interventions could address overuse. Further efforts are 
also needed to examine causality using longitudinal data.
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